



## Biacore BioPharmaceutical Symposium

From Drug to Market

Dublin, Ireland  
October 11-12, 2007

### Symposium Agenda

Please note, content and timings are subject to change.

---

Thursday 11<sup>th</sup> October 2007

Registration and Lunch – 12pm onwards

<p><b>Opening Remarks</b> 13:30</p>	<p><b>Dr. Fredrik Sundberg</b>, GE Healthcare, Uppsala, Sweden</p> <p><i>From a Global Industry Perspective: SPR Biosensor Strategies to Improve Bio-therapeutic Discovery and Development</i></p>
---	--

### Session 1: Antibody Screening

<p><b>Chairperson:</b></p>	<p><b>Dr. Trevor Wattam</b></p>
<p><b>Time:</b> 14:00</p>	<p><b>Dr. Trevor, Wattam, GSK, Stevenage, UK</b></p> <p><i>High Throughput Monoclonal Antibody Screening using the Biacore A100</i></p>
<p>14:45</p>	<p><b>Dr. Bruce Carrington, UCB-Celltech, Slough, UK</b></p> <p><i>Antibody screening prior to cloning</i></p>

**COFFEE BREAK: 15:15 – 15:45**

## Session 2: MAB / Recombinant Protein Development / Characterization

Chairperson:	Dr. Kenneth Miller
Time: 15:45	<p><b>Dr. Kenneth Miller</b>, MedImmune, USA</p> <p><i>Use of SPR Biosensors in the Characterization of Therapeutic Mabs</i></p>
16:30	<p><b>Dr. Danièle Altschuh</b>, University Louis Pasteur CNRS, Strasbourg, France</p> <p><i>SPR characterization of gastrin binders, for the development of anti-gastrin therapies in pancreatic cancer</i></p>
17:00	<p><b>Dr. Alistair Henry</b>, UCB-Celltech, Slough, UK</p> <p><i>Antibodies, epitopes and mechanism of action</i></p>
17:30	<p><b>Dr. Martin Heülsmeier</b>, Pieris AG, Freising, Germany</p> <p><i>The role of SPR based assays in the discovery and lead optimization of Anticalins®, a novel class of therapeutic binding proteins</i></p>

**End of Session – 18:00**

**Conference Dinner**

---

**Friday 12<sup>th</sup> October 2007**

## Session 3: Process Development including PAT

Chairperson:	Dr. Mathilde Cabrit
Time: 08:45	<p><b>Dr. Mathilde Cabrit</b>, Merck-Serono, France</p> <p><i>Biacore C versus Other methods For Ab and fusion protein quantification in cell culture and purification processes</i></p>
09:30	<p><b>Dr. Anthony Newcombe</b>, Protherics, Wales, UK</p> <p><i>Evaluation of Biacore Technology for Biopharmaceutical Development</i></p>
10:00	<p><b>Prof. Gregory de Crezenzo</b>, École Polytechnique de Montréal, Canada</p> <p><i>On-line Monitoring of Bioreactor Protein Production by Surface Plasmon Resonance</i></p>

**COFFEE BREAK / POSTER SESSION: 10:30 – 11:00**

### Session 4: Immunogenicity

<b>Chairperson:</b>	<b>Dr. Daniel Mytych</b>
<b>Time:</b> 11:00	<b>Dr. Daniel Mytych</b> , Amgen Inc., USA <i>Immunogenicity of Therapeutic Proteins</i>
12:00	<b>Dr. Annette Zaar</b> , Novartis, Basel, Switzerland <i>Detection of Anti-Drug Antibodies (ADA) in the presence of excess Therapeutic Antibody</i>

### LUNCH / POSTER SESSION: 12:30 – 13:30

### Session 5: Validation and QC

<b>Chairperson:</b>	<b>Dr. Thomas Urbig</b>
<b>Time:</b> 13:30	<b>Dr. Thomas Urbig</b> , Micromet, Germany <i>The use of Surface Plasmon Resonance Spectroscopy from Development into Early Manufacturing</i>
14:15	<b>Dr. David Thakor</b> , GSK Beckenham, UK <i>Delivering next generation BiAcCore assays into the QC environment</i>
14:45	<b>Dr. Cornelius Fritsch</b> , Novartis, Switzerland <i>Effector Functions of Therapeutic Monoclonal Antibodies: Analysis Using Biacore Technology</i>

<b>Closing Remarks</b> 15:15	<b>Dr. Lisa Jennings</b> , GE Healthcare, Amersham, UK
---------------------------------	--

### COFFEE AND DEPARTURES: 15:30 ONWARDS